Michael E. DeBakey Department of Surgery, Division of Pediatric Surgery, Texas Children's Surgical Oncology Program, Texas Children's Liver Tumor Program, Dan L. Duncan Cancer Center, Baylor College of Medicine.
School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
J Pediatr Hematol Oncol. 2021 Nov 1;43(8):e1181-e1185. doi: 10.1097/MPH.0000000000002089.
Children with unresectable hepatocellular carcinoma (HCC) have a poor prognosis and limited treatment options. Transarterial radioembolization (TARE) using Yttrium-90 (Y90) has emerged as a potential bridge therapy to hepatic resection or transplantation for HCC with very limited studies in children.
Here we present the clinical course of 2 children successfully treated with TARE Y90 for initially unresectable fibrolamellar HCC (FL-HCC) and bridged to partial hemihepatectomy with >1-year overall survival post-TARE.
Although there have been prior published reports of pediatric patients with HCC being treated with TARE Y90 and some being able to undergo subsequent orthotopic liver transplantation, this is the first report of pediatric HCC patients treated with TARE Y90 as a bridge to nontransplant resections and going on to have >1-year overall survival.
无法切除的肝细胞癌（HCC）患儿预后较差，治疗选择有限。钇-90（Y90）肝动脉内放射栓塞术（TARE）作为肝切除或肝移植的潜在桥接治疗方法，已经应用于 HCC 治疗，但在儿童中应用的研究非常有限。
在这里，我们介绍了 2 例儿童患者的临床过程，他们最初因无法切除的纤维板层 HCC（FL-HCC）而接受 TARE Y90 治疗，并通过 TARE 后>1 年的总生存时间桥接至部分半肝切除术。
尽管之前已经有关于 HCC 患儿接受 TARE Y90 治疗的报道，并且有些患儿可以接受后续的原位肝移植，但这是首例报道的接受 TARE Y90 桥接非移植切除并实现>1 年总生存的儿童 HCC 患者。
